Designation applies to the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma ...

Head and neck cancer is diagnosed in at least 700,000 patients each year. A team of 27 doctors has found a comforting means ...

Mean dose to the tongue mucosa did not improve predictions of taste impairment during and after radiation therapy compared ...

DUBAI, United Arab Emirates;February 2025 - Throat cancer is one of the fastest-growing cancers, and it is often linked to ...

University of Pittsburgh School of Medicine and UPMC Hillman Cancer Center scientists have discovered a novel subset of ...

Merck & Co. has won U.S. Food and Drug Administration priority review for its application seeking expanded use of its blockbuster cancer drug Keytruda in certain patients with head and neck cancer.

Ficerafusp alfa enters phase 2/3 trial for recurrent/metastatic head and neck cancer, evaluating its combination with ...

A physician-scientist at the University of Oklahoma is part of an international effort seeking new options for patients with head and neck cancer who cannot receive the standard chemotherapy drug ...

KEYTRUDA monotherapy is the recommended first-line treatment for recurrent or metastatic HNSCC with high PD-L1 expression, ...

Purple Biotech (PPBT) is advancing into a Phase 2 study with NT219 in patients with recurrent/metastatic squamous cell carcinoma of the head ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

Professor and surgeon Jason Hunt, MD, MS, FACS, has been named inaugural Chair of the Department of Otolaryngology – Head and ...